Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis

ABSTRACTToday, more than 90% of people with cystic fibrosis (pwCF) are eligible for the highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy called elexacaftor/tezacaftor/ivacaftor (ETI) and its use is widespread. Given the drastic respiratory symptom improve...

Description complète

Détails bibliographiques

Auteurs principaux:	Catherine R. Armbruster, Yasmin K. Hilliam, Anna C. Zemke, Samar Atteih, Christopher W. Marshall, John Moore, Junu Koirala, Leah Krainz, Jordan R. Gaston, Stella E. Lee, Vaughn S. Cooper, Jennifer M. Bomberger
Format:	Artigo
Langue:	Inglês
Publié:	American Society for Microbiology 2024-05-01
Collection:	mBio
Sujets:	cystic fibrosis Pseudomonas aeruginosa evolution pathogenesis respiratory pathogens lung infection
Accès en ligne:	https://journals.asm.org/doi/10.1128/mbio.00519-24
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!